Epizyme Total Liabilities 2012-2022 | EPZM

Epizyme total liabilities from 2012 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Epizyme Annual Total Liabilities
(Millions of US $)
2021 $310
2020 $289
2019 $93
2018 $42
2017 $54
2016 $51
2015 $48
2014 $39
2013 $59
2012 $155
2011 $88
Epizyme Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $301
2021-12-31 $310
2021-09-30 $317
2021-06-30 $285
2021-03-31 $284
2020-12-31 $289
2020-09-30 $137
2020-06-30 $134
2020-03-31 $111
2019-12-31 $93
2019-09-30 $40
2019-06-30 $46
2019-03-31 $44
2018-12-31 $42
2018-09-30 $31
2018-06-30 $34
2018-03-31 $29
2017-12-31 $54
2017-09-30 $52
2017-06-30 $55
2017-03-31 $49
2016-12-31 $51
2016-09-30 $45
2016-06-30 $46
2016-03-31 $44
2015-12-31 $48
2015-09-30 $48
2015-06-30 $36
2015-03-31 $35
2014-12-31 $39
2014-09-30 $48
2014-06-30 $49
2014-03-31 $50
2013-12-31 $59
2013-09-30 $60
2013-06-30 $66
2013-03-31 $0
2012-12-31
2012-09-30 $0
2012-06-30 $0
2011-12-31 $88
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.244B $0.037B
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00